Method for Obtaining Non-Stochastically Generated Polypeptides that can induce a Broad-Spectrum Immune Response.





Figure 17


Possible factors for determining whether a particular polynucleotide encodes an immunogenic polypeptide having a desired property.



protein purification In vitro analysis
-FACS
-ELISA
-Phage display HTP plasmid or Robotic colony picking (pools or individual) Screening strategy for antigen library screening. Immunization/ challenge -survival of mice -serum/spleen inducing crossprotective Identification of clones immune responses evolved Ags Library of

Figure 19

Strategy for pooling and deconvolution as used in antigen library screening



Nucleic acid sequences that can be mutagenized by

1. SEOUENCES TO BE MUTAGENIZED

non-stochastic site-saturation mutagenesis include

(e.g. any coding region & any non-coding region). any polynucleotide of 15-100,000 bases in length

Specific examples:

• Promoter Enhancer

 Polynucleotide functional group Expression regulatory sequence Expressed sequence (ag (EST)

Open reading frame (ORF)

Whole gene

• CDINA

● Intron


Repressor/transactivator

 Origin of replication Gene pathway

Gene segment

Operator

# Figure 20. Preferred embodiments of site-saturation mutagenesis



### II. MUTAGENIC CASSETTES WITHIN SEQUENCE TO BE MUTAGENIZED (

example, a set of mutagenic cassettes is a set of nucleotide cassettes that are not shared by aligned codons within a sequence of defined length. Alternatively, in another preferred but non-limiting differently (i.e. immediately adjacent, evenly spaced, or unevenly spaced) and of any size. In a preferred but non-limiting exemplification a set of mutagenic cassettes is a set of contiguous include any polynucleotide cassette of 1-500 bases in length. Site-saturation mutagenesis is sequence to be mutagenized. As shown, cassettes can be spaced along each polynucleotide Mutagenic cassettes that can be mutagenized by non-stochastic site-saturation mutagenesis servicable for mutagenizing a complete set of cassettes contained within a polynucleotide related polynucleotides

## TYPES OF MUTATIONS THAT CAN BE INTRODUCED INTO MUTAGENIC CASSETTES

The type of mutations to be introduced in a set of mutagenic cassettes can be of the same type or mutagenized by the use of a corresponding oligo (including by a degenerate oligo). Examples of of different types within each round of polynucleotide site-saturation mutagenesis. Each mutagenic cassette (within the nucleic acid sequence to be mutagenized) preferably is usually degenerate mutations provided by this invention include:

Codons for all 20 amino acids (e.g. N,N,N or N,N,G/T or N,N,G/C)

All degenerate codons that do not change the amino acid sequence of the parental template (i.e. codons for the same amino acid that is present in the parental template)

Codons (all or selected) for amino acids within the same grouping according to the selected amino acid grouping scheme\*.

Codons for at least 1 amino acid in each amino acids group\*.

\*Exemplary amino acid grouping schemes (notes, some groups overlap each other):

 Acidic (Asp, Glu, Asn, Gln) Aromatic (Phe, Trp, Tyr) · Basic (Lys, Arg, His) · Aliphatle (Gly, Ala, Val, Leu, Ile)

 Sulfur-containing (Met, Cys) · OH-containing (Ser, Tyr, Thr)

Non-polar (Gly, Ala, Val, Leu, Ile, Met, Phe, Trp, Pro) Polar (Ser, Thr, Cys, Asn, Gln, Tyr)

Figure 21

Schematic representation of a multimodule genetic vaccine vector (relative sizes of functional units are not drawn to scale)




Figure 22A and 22B Generation of vectors with multiple T cell epitopes.





Figure 23

### Generation of optimized genetic vaccines by directed evolution



Recursive application of directed evolution and selection of evolved promoter sequences as an example of flow cytometry-based screening methods.





Figure 25
An apparatus for microinjections of skin and muscle.



### Figure 26 Panel A

Non-stochastic polynucleotide reassembly in combination with non-stochastic polynucleotide site-saturation mutagenesis.

Shown below is a non-limiting example of a permutation of the directed evolution methods described herein




Figure 26 (continued) Panel B

Screening of experimentally generated molecules produced by non-stochastic polynucleotide reassembly in combination with non-stochastic polynucleotide site-saturation mutagenesis




Figure 27

### Vector for promoter evolution





Figure 28

Iterative evolution of inducible promoters using directed evolution and flow cytometry-based selection.



The present invention provides that a genetic vaccine can be subjected to directed evolution in order to achieve improved effectiveness upon administration by oral, intravenous, intramuscular, intradermal, anal, vaginal, or topical delivery methods.

The figure below shows an example of the directed evolution of a genetic vaccine, comprised of an M13 phage-based vaccine, to achieve optimization for oral delivery.




Figure 30

An alignment of the nucleotide sequences of two human CMV strains and one monkey strain.

•				•	_
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1)	CTACTO		TCCAGCACGCCGGC	CATCATCAGGCCC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(49)	TCGATHERE	ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ	Ñ <b>©~-ĞĞİ</b> CİĞG-ĞC	CGCGGGGGGGCCTC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(94)	GTCICCCGT	CĂĨĨĠĀŨŦĠĀĢĠŦŎĬĬ ĠĀĨĨĊĀĨĠĊĢĨĠĠĬĠĠ ACĀŦĨĬŦĊŦĢĀĀĠĔĀſ	CGCGGROGTIT	CAACCCTTTCCTTCC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(142)	GEOEGCGG	gaa <b>ā</b> tēcēja <u>tīmo</u> aē - Ēgācējagtījoēcē - Ēgācējagtījoē	TTTCTCCCCCCCCC	<u>ශේලී්උදිඋදුඋදුවනන්දීයි</u>
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(191)	CGG-GREAT	- <u>Ā</u> З <u>Б</u> САТОТАБЕЎЁ. ГОВОБОТВОТВОТВОТВОТВОТВОТВОТВОТВОТВОТВОТВОТВО	CŤTCTCĞĞĞĞĞĞĞĞ	CAAATCAGCTCCA
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(240)	G-GTATCGG	iamcactoactica Ianacticcictic Igaganiatataa	TCĞTÄGGĞĞĞCGÇ	CATCATICATOR
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(289)	GAAGGAGAG	acgtagatggfaag Tygeatggecfe Tygege-togatgg	GGGTÄÜĞGGGTÖ	ACCCT-CCCCAC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(337)	CGECAGGAT	agaettá———age teáscaca——eaga gaaccettcette	GGGGAGGGTCACC	COTOTACCOTOTO
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(384)	AAPPGGAGTZ	ŒŢĠŦġŦĠŦĠŦĠŦĠŦĠŦĠŢ ŒŖĠŖŢĠĠĊŢĠŢŖŢ ŒŖĸţĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ	CGCCCCTGATGG	GTGACGAGAC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(432)	GCGGCAGGCG	CÅĠactctca XXÁGGTGGG XATCCAGGAGACTÁC	ATACTCCTTTTCC	CACAGCTGCG_T
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(451) ( (478) (	gaggaagegt	<u>ŦŒŢŖĠĊĸĸĠŖ</u> ĸĸŧijt Ţ <u>ŒŖŖĠ</u> ſĠĸĊŧŢĠĸĸŧijt	CĞĞĞĞÇĞĞA ACTÎ	C-GAGAGAGAG

### Figure 30 continued

AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(527)	551 CTGAACTTGACGGGAGGGAGGGGGGGGGGGGGGGGGGGG
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(551) (571) (579)	650 GRANGGCCHACGTGTGTTTTCACANGGGTGTGGANGRA-ANGCCCA AGGGGCCGCGGGGGCGCGCGAGGGGGGGGGGG
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(597) (615) (627)	The second of the second secon
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(646) (657) (677)	CTICGEGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(689) (706) (725)	800 <u>GENTULA GETGA GIJECT BAJARCEAN IIII — RECITE AAGET TETET TEGE</u> <u>GEORGE CON GETGE TEGET TEGE</u> TEGET <u>GETTE GATET GETAT TEGE</u> AGECCTEGE GE ATCGGAGECC GATECCT TEGET TEGET ACT TEGET
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(736) (756) (775)	850 CETGAA KOTEGAGĀ ĢĀ ŢGAATA ĀĀ ĢA — ĀGCTĒ ĀAGGA ĢĀ ĢĒ ĀGT ŢĪĪG Ţ CETGE ĢĒ TĒGĒ TCTĒ CĒ br>GAAGĒ TĀ GETGĀ ĀĀ TĒTAT ÇC ĢT TĒG TAĀAA TĒŠĀ ——— ĢĀ ĢĒ TĒJĀ TĀAC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(784) (801) (821)	960 ŢĠĨĬĠĨĬĠſĬŢĠſĬŢĠſĬĬĬĸĠŢĊŢſĊĠŢŢĠĊĊĸĬĬĬŎĸĠĬŢĠŢĊĠŦĊĊĠĊĸĠŢĠ ŢĸĬĬĊĬĸĠŖijĠĠijŎĬŢĠĸŦĊĠĊĠĔĠĊĠĠĠĊĠĠĠĊĠĠĠĊĸĠĠĊĠĠĠĠĠĠĠĠĠĠĠĠĠĠ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(834) (847) (863)	950 QAĞĞCAAÄTTĞTAĞAĞBAĞAAÄAGĞTGACCÜĞGAĞAĞAĞGĞÜÜÜÜ QÜÇÇĞÇĞÇĞĞÇĞĞÇĞĞĞĞĞÇÇĞĞĞÇĞÇĞÇĞÇĞÇĞÇĞÇĞÇĞ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(896)	1000 ŢŢŢĊĸŢŢŢŢŢĠĠŢĠŦŢĠŢŖĠŖĸŖĸŖĸŖĸŖĸŖĸŖĸŖĸŖĸŖĸĸĸĸĸĸĸĸĸĸ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(942)	1001 <u>GAĞT GĞ</u> GÇÇÇÇÇTAĞAAĞĞCLANAĞĞLAAATĞ <u>ÇAĞA</u> ATACAGGAĞ GACÇĞTTTTĞCÇTÇÇAĞÇÇAĞ <u>EÇGAAĞGÇ</u> ÇÇAAĞTÇCTĞÇAĞĞ ÇCÇĞAĞAAÇĞGACGAA-AĞĞ <u>ÇĞZ</u> ÇĞTÇ <u>Ö</u> ĞTTAĞÇÇÇĞAT———AAC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(984) (986)	1051 ÁÁTGTGÁAGGÍAGTGGAAÁÍAAAGÁGATG—ATÉGAÁGCACTAAAGCAAT GÁGTCGÁCGÍTGTCGTCGÁTGGCGÁTTGCGATTTGCTGTCCGAGACGTT ÁTGGAAÁTGTTGTTGA—GÁTGGGGCTTTC———TTAAGGTCCGTGGCÁTT
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1032) . (1036) :	1101 ÅTGÖTÄŸGGACŸATŸĆĠAATÄAAĞÜŸſĊŸTĞAGĂAĞGGACŸGAATCCTCYĠ ÄAĞĞAŸAAACŸĬſĊĄĬXATĞĞACŸTTY-ŢĞĞÇĞTCĞCŸ-ĞCÇCCGGTCGYĞ ŘCĠĞGÄŸŢŶĠĄCĠĞCĠĞÄTŸĞĞG-ŸĞĞĞĞTĞCŸCĞTÇTGĞAGAĞŸĞ

### Figure 30 continued

AF026939 CM AF047524 hum UL104	7 (1082)	1151 AATSATACICCGATTITECTGAS-TECTEGASACGGAARGTTATCAGA
AF078102 Rhesus		1000
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1131)	TGGEGERRACCAETTREAGAEGAAAGGTATTGAGGAAETGGGAGATA
:		TATGGTCATCHEAGTTACCCCCAGCAGCCC 1251 1300
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1178)	CAŢCĂŢCĀŢŢŢĊŢĸĊŢĠĊĸĸĊĠŢŢĠŖĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF026939 CMV	(1222)	1301 1350 CACTGETGTGATCATEGETTTAGACT-GTTTGTGCATARGOAAAA
AF047524 hum UL104 AF078102 Rhesus	(1226)	TGTGCEACGGGGTTGTTEAKCASCASCATCTTGTGGGGTGATAACCCAGC AATTAGETAGCTGTTGTTGGGGGACGTAGTGATTTGATGCCTAGC
AF026939 CMV AF047524 hum UL104	(1266)	1351 AATCAACTGAĞAĞĞ GAĞGATCAĞAĞAÇĞACĞACAĞAĞTGTATÇCĞĞ
AF078102 Rhesus	(1267)	ĠŢŢŢĊĠĠĬĊĠĊĠĊĠĊĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF026939 CMV AF047524 hum UL104	(1315)	1450. AAATCTGGTTCCACAAAATGGACGAAATTATTGGTATCTTCAAGGA
AF078102 Rhesus	(1317)	©CAGCCGCTCGGECCCARETTTCTTGAAGACGCTTACCTCGGGC CGGTTCTAGAAGCGCCCCAAAGCGGTGGGTGGGAAGAAA
AF026939 CMV	/1361)	1451 1500
AF047524 hum UL104	(1367)	ŢŢĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF078102 Rhesus	(1356)	ATGATGAGTTĀĀGGGĀGĀĀĀĀĢGTĢTGATGĞTĀCTGŢGĀTĞŢŢTÇGT
AF026939 CMV	(1411)	1550 GANGGANGTEGGCCGGGTGGTAAGGGATGGCGGTTGAGGCAAAAGGC
AF047524 hum UL104 AF078102 Rhesus	(1413)	GCNGCGCGAGGTTTAGCGTGEAGGTGGTGGGGGGGGGGGGGTGTGTCT-C
Aru/8102 Rnesus		GTAGACAGAGGTTTTTCTCGCAGAAGGGTAAAGTTTGGAGGGTGAAAGC
AF026939 CMV.		1600 AĞĪATTĒTĶCTGT <u>ČĀ</u> ÇCATĠŢ <u>ĞĀĞĞ</u> TĪĞĀĞĞĀĀŢĠĞT—ĀĞŢĠĀĞGĀAĀTĠG
AF047524 hum UL104	(1462)	GGTEGGT-EGGTGCAC-GGECECECTACAAAFTGEECCCCCTCGGCC
AF078102 Rhesus	(1451)	ĠĸŢĠĸĠŢĸĠĸĠĸĠĸĸĠĸĸĠĠĸĠĠĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF026939 CMV		1650
AF047524 hum UL104	(1508)	ĢĒJAGGĢĒ-GŒĀĢTĢAĢCŢĢCAĞŢĒĢCĀGĀĢAĢCŢCĢTCTĢTAĀCŢC ĢĒĢĪĒ-ĢĒ-ŢĒGGĒTŢĢGŢĒŢTCACĢĪĢĒAGÇĀĢCĢGŢĀŬÇĀGTCCC
AF078102 Rhesus	(1501)	CCCTCACCATTRECCTCTTGTCATTCTTTCACAT-CAAACAAACGCC
AF026939 CMV		1651 <u>ÁGAĞCAÄĞTĞAAĞTGAĞGAĞĞĞĞĞĞĞĞĞAĞĞÇ—ATÇÄGAAĞÇ</u> ÇT
AF047524 hum UL104	(1553)	ACCGTTAC-GCACCAATCGACGTAGAGACCATAGTCGTCGTTATCGCCCCT
AF078102 Rhesus	(1547) 2	ACTOTTGATTOTTATCATESTGAGAGTGAGOCATCTCTGT
AF026939 CMV		1750
	(1602)	3GAGTGGTGGTTGTEXCGGGTAGGAGGATAGGAAGAGAGAGGGGGCGCCAA \TTGATATAAA—ATGTCGCG——GAGGGGGGGGGGGAG—G——ACGCCCGTTT
AF078102 Rhesus	(1587)	CTCAGATACCCATGATCGACCACCCCCAGACATTATGGCCATAA

Figure 31


An alignment of 11\_4 nucleotide sequences from 3 species (human, primate, and canine).

AF187322 Canis IL~4	1 1) TGCATGGTTAGGGTCTCCTAGTAAAGGGTTTGTCTGTCACTGC
NM 000589 Homo sapien IL-4	1) TECNTOTTIACOTTOTCOTCATANOTIANOTO-GCCTCACATTGTCACTCC
<del></del>	1)
013030 Cercocengs III-f	
	51
AF187322 Canis IL-4 (5	1) ANATHAGRGATCTATTAATGCCTCTCTCCCAACTCAACTCTCCG
· · · · · · · · · · · · · · · · · · ·	0) ATATCGACACCTATTAATGGCWCPCAGCTCCCCAACTCCTCCCCCCTCTGT
<del>-</del>	1)ATGGGTCTCAGGTCGGAACTGCTTCCCCCCTCTGT
013030 Cercocends In-4	
	101 150
AF187322 Canis IL-4 (10	1) TETGETTAGTAGGACTCAGGACGTTTGTCCACGGACATAACTTCAAT
NM_000589 Homo sapien IL-4 (10	The same of the sa
U19838 Cercocebus IL-4 (3	5) TOTOGOTOSTAGEATGTGGGGGAACTTTGGGGATGAACACAACTGGCAT
013939 Cercocends IT-4 (2	2) II all and the second and the second and the second
	151 200
AF187322 Canis IL-4 (15	1) ATTAGTATTATACACATTATCANATTGTEGACATCCTCACACCCGAGAA
NM_000589 Homo sapien IL-4 (15	The state of the s
U19838 Cercocebus IL-4 (8	5) ATGGGGTTAAGGGGAGATCATGGAAACTICTGAACAGGCTCACAGAGC-AGA
019838 Cercocepus 11-4 (6	2) KITCHTHE THE CONTRACT CONTRACT THE CONTRACT C
	201 250
AF187322 Canis IL-4 (20	1) CONTRACTOR OF THE PROPERTY
	9) REACHETETESECCERCTEGREEGTERCAGRETTTTGCTGCCTCCARG
U19838 Cercocebus IL-4 (13	4) AGASTOTOTOCACCATOTOTACCATARCGGACATCCTTCCTGCCTCCAAG
019838 Cercocepus 1D-4 (13	4) WENELLAND AND CHANGE TO STATE STA
	251 300
AF187322 Canis IL-4 (25	O) ANGAGARGCGATANGGAAATCTTGTGGAGAGCTGGTACTGTACTGCGGGA
	9) AACAGACTGTGTAAGGAAAGGTTCTGGAGGGCTGCGGACTGTGCTCCGGCA
	4) ARCAGARTIGAGAAGGAARCCTTTTGCAGGGCTGCGACTGTGCTCCGGCA
U19838 Cercocebus IL-4 (18	1) Wachevallowagastectanadactocatetrataciccacv
	301 350
AF187322 Canis IL-4 (30	O) CATCTATACACACAACACG
	9) GTTCTTEGAGCCAECATGAGAAGGACACTGGGTGCGGTGC
U19838 Cercocebus IL-4 (23	4) GTTCTACACCACCATGAGAAGGACACTCCCTGCCTGCGTGCG
013020 Cercocepus ID-4 (52	1) entre Merre de Charavada de descretar de crista de de de de de de de de de de de de de
	351 400
AF187322 Canis IL-4 (31	anticulate white white and the second of the
	9) AGEAGTTEGACAGGCAGAAGGAGCTGATCCGATTCCTGAAACGGCTCGAC
	a har the second
U19838 Cercocebus IL-4 (28	*) Wardeliketerkalerteterkeringeliketerkering tattiscales ciake
	401 450
35107222 Canid II.4 /2/	and the second s
AF187322 Canis IL-4 (34	NGGAAGCTGAGCAGAAGGGAAACAAAAAAAAAAAAAAAAA
	Control of the Contro
U19838 Cercocebus IL-4 (33	1) AGGARCTICHTGGGGCTTGGGGCTTGAACTCCTGTGAAGGAAGC
	451 500
ami 07700 Camio Tr 4 470	
AF187322 Canis IL-4 (39	3) <u>CANGAAGACTACACTIGAANGACTICTITTEGANAGCCTAANGACGATCATGA</u> 9) <u>CAACCAGACTACCTTCGANAGCTICTTCGANAGCTAANGACCAT</u> CATGA
NM_000589 Homo sapien IL-4 (44 U19838 Cercocebus IL-4 (38	A) CACCAGACTACGTTGGAAGACTTCTTGGAAAGGTTAAAGACGATCATGA
UI9838 Cercocedus IL-4 (38	THE THORIST HOUSE THE ANGEST OF THE PROPERTY O
	501 550
50107299	550 3) AGAJGNANTACTACAGGCATTGAAGCTGANTATRITTATTATGAGTTTT
AF187322 Canis IL-4 (44	ACAMONATION THE ANGLE THE
NM_000589 Homo sapien IL-4 (49	) GAGAGLANTATTCAANGTGTTTGGAGGTGAATTATTATGAGTTTT
U19838 Cercocebus IL-4 (43	) GAGAGAAATATTICAAAGTGTTCGAGCTGAA

### Figue 31 continued

AF187322 Canis NM_000589 Homo sapien U19838 Cercocebus	IL-4 (549	IG-ATAGOTTA THE TTANGTATURA TATALA PARACTCAT	000 Ataata Aaataa
AF187322 Canis NM_000589 Homo sapien U19838 Cercocebus	IL-4 (598	TERACTATATAGAATCOA	

Evolution of polypeptides by synthesizing (in vivo or in vitro) corresponding deduced polynucleotides and subjecting the deduced polynucleotides to directed evolution and expression screening subsequently expressed polypeptides.



Optionally repeat

CG : CpGs that may be beneficial (or have neutral effects) when added in (in the context of all

other mutations, if any)

### Figure 33

### Directed evolution of polynucleotides (e.g. promoter sequences)

This figure shows an example of the application of non-stochastic site-saturation mutagenesis in combination with non-stochastic reassembly (e.g. oligo-directed CpG deletion(s) and/or addition(s))




Figure 34

An example of a CTIS obtained from HbsAg polypeptide (PreS2 plus S regions).




Figure 35

An example of a CTIS having heterologous epitopes attached to the cytoplasmic portion.






Figure 36

Method for preparing immunogenic agonist sequences (IAS).



Poly-epitope region containing potential agonist sequences



Further optimized poly-epitope region containing potential agonist sequences

Direct evolution (+/- screen)
Repeat as desired

Figure 37
Improving Immunostimulatory Sequences (ISS) Using Directed Evolution.




Figure 38

Screening to identify IL-12 genes that encode recombinant IL-12 having an increased ability to induce T Cell proliferation.




Figure 39

Model of induction of T cell activation or anergy by genetic vaccine vectors encoding different CD80 and/or CD86 variants.




Figure 40

Screening to identify CD80/CD86 chimeric genes having an improved capacity to to induce T Cell activation or anergy.





Figure 41

Figure 41. An alignment of two CMV-derived nucleotide sequences from human and primate species.



### Figure 41 continued

AF078102 Rhesus M67443 Towne	(682) (620)	750 FAAGACCGCAGASGAGTTTCATGGGGTTTTCCTTGGGGTTAGTCAGAGAAGGC- GGCAGGTGATAGGTGACCGGTAGGGTGTACCTGGAGTTCTTGT
AF078102 Rhesus M67443 Towne	(731) (668)	751 EGECEATEGGAEGEGATCCETTE CACCET CA
AF078102 Rhesus M67443 Towne	(779) (717)	801 CTPOCETCARRICGTATECCTTTCCIIARAATGAGEGETGATEAGETIIAGEAA TGAGGEGGAEGAGGAGGTGACGAEGEGCGCAECGCAECGC
AF078102 Rhesus M67443 Towne	(829) (767)	900 TOTE STAMAGTATATTANECAN CATCELLATOR TORONO CONTROL OF CONTR
AF078102 Rhesus M67443 Towne	(871) (817)	950 EGTTGTTGTTG-DIGGG-EGUTACEGIAATHTGGAATGTGGG ATGAALGCGGCCAACHTGTCGGAGAGCATGGGAUGGCCTGUUACGC
AF078102 Rhesus M67443 Towne	(917) (867)	1000 NGCTATEGRAMANTACTATIEGACIAETGEGGCGTETGETATETEG-EG NGACIAECATE-BEGGECZECT-ETCZICECAALAECALCCCEGEGCEG
AF078102 Rhesus M67443 Towne	(966) (914)	1050 GAMEGACGAAIGEGACGTTTTEGTCTTOGCEFFAAGATGT GCATGTCAGGTJAGCTATIGAIGAAGGGCAGGAEAI TTEEGTGGAGG
AF078102 Rhesus M67443 Towne	(1014) (962)	1100 TETTCAGATEZEGCTATETTANGCTEGETEGCATTANGCGATTTCAGCGC TGCAAGCAATAAGCCAGA-GTERGCAGCTCAGAAC
AF078102 Rhesus M67443 Towne	(1064) (1000)	1150 GENTTGECTGEGAGEOTEGTCTGETGEGTENGT-ECTACTCTTT -GATCCEGTGEGTGGGTTGGTTTTCGATTTCGATTTTCGATTTT
AF078102 Rhesus M67443 Towne	(1109) (1048)	1200 DA GOTGA CAGTA AGCANGA TOTOTOTOTOTOGA GOTTOTATOGA GOTTOTOGA GOTTOTOTOTOTOGA GOTTOTATOGA GOTTOTOTOTOTOGA GOTTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTO
AF078102 Rhesus M67443 Towne	(1159) (1096)	1201 1250 TA CGCCGA GGCTCT TEGTGGT T-AGGA GGCCTCT GCGCT GTTAT AT CGA GGCT AGCTT AGTAC GACACAC TEGG - AGCGCT CGACG
AF078102 Rhesus M67443 Towne	(1208) (1142)	1300 CGCGCTGATGATĀAAATACĀTĀGCĀGTĀGĀTĀTTGGĀGACGĀAĀTGAĀTT AGGĀTGĀCGCCCĀGGGCGAĀGĀĀGĀCĀĀCĀĀCĀĀCĀ
AF078102 Rhesus M67443 Towne	(1258) (1192)	1350 TECCTECTECTECATE TANTO CANTO ATTGET TO THE CONTROL CACCAGG AGT CONTROL TO THE CONTROL TO TH
AF078102 Rhesus M67443 Towne	(1308) (1241)	1400 SEAGTETE CEGTTCTABAAEGEE - ECTAAGGGTTGCGTGGAABAG GGGCGCGTTGG

### Figure 41 continued

AF078102 Rhesu M67443 Town		14.00 E M. 19 15.00 J. 10. 10. 10. 10. 10. 10. 10. 10. 10. 10
AF078102 Rhesu M67443 Town		1451 A-GAGAGAGATTTTTCTGCCAGATGCCTAAAETTGGAGGGTTAAGGGAT CCGCGTTTAAGGCCGAGTGGTGGGACGCCGCGAAGAGAGAGAG
AF078102 Rhesus M67443 Towns	•	THE THE PERSON OF THE PERSON O
AF078102 Rhesus M67443 Towns	. ,,	1551 TEACCATCAGECTETTETEATTCATTAGATCAAACAAACGGTAGTETE GECCECCTGECAGECCEGEATCCEGGCCGCCACCCEATGETEC
AF078102 Rhesus M67443 Towne	(1554) (1475)	1601 AMT TTAMGATGANGAGAGTCAM-ATCTGECM-EAGATAGCGA CMAGGGTMCAGGGCCAGAAGCAGGAGGAGGTGGTGGGAGGGG
AF078102 Rhesus M67443 Towne	, 7	1700 TGAT CAECAGCCGGAGAGATTATICS CEATAAGCAAACGAATTCGGAGC AAGGAGATGTACGGCAUCTTGCGCGAATTGGGAAGGCGTTATCGGAGC
AF078102 Rhesus M67443 Towne	(1648) <sup>·</sup> (1571)	1750 
AF078102 Rhesus M67443 Towne	(1689)	1800 SGEGEGEASGAGEA-EGTATECĂTATGAAATAGIGECATTGTTECET GCEATICATCGGCTECECCAEAAATAGIGETEAGCCACCECCC
AF078102 Rhesus M67443 Towne	(1735)	1850 GAAĀGGGTĀĞÇĀ———— ĪITĪĀTGĀÇĀGTTĒAATGŪRĀŢĀTTĀĀĪT ĢCGCĀCĒCĪĪĀGGĀCGACTCĪĀŢĀĀĀĀĀĀĀĀĀĀTCĀTCCĀĢĀĢĀÇĀĢG
AF078102 Rhesus M67443 Towne	(1779)	1900 GETGETGEATTAAATTAATTAATTAATTAATTAATTAATTAATTAA
AF078102 Rhesus M67443 Towne	(1827)	1950 COTGTEATURETECTTGEAGTGGTGEGAMAKATIIAETAETAGAET GGAAGCCIIIGCGGAGCTCCCACGAGGACCACGGGGAGACCACGGAGAGACGACGGGGAGAGACGAGAGAGACGA
AF078102 Rhesus M67443 Towne	(1877) -	2000 BAĞCƏRATÜAĞITTGTGAAAGƏNGAĞITBAAĞANCATGCAATRIĞINGGĞAĞGA BCQCOGCCCCC BOZOTTGAÇGĞATCGCGATGAÇÇA
AF078102 Rhesus M67443 Towne	. 2	001 2050 CTGGGGGGGTTGGTTTGTGTTTTTTTTTTTTTTTTTTT
AF078102 Rhesus M67443 Towne		051 GETTEARETETTTTTTTTTA AGGCEGETTCGCE-EGCGARGCTT
		•